Pharmacologic agents are commonly used to treat psychiatric diseases. These compounds, however, react differently across patients, are often followed by negative side effects and can have varied efficacy timeframes.
Stanford scientists have developed a set of preclinical assays that are specifically designed to detect empathogenic effects of a drug that may indicate applications for that molecule in treating psychiatric diseases like PTSD.